TS-1 enhances the effect of radiotherapy by suppressing radiation-induced hypoxia-inducible factor-1 activation and inducing endothelial cell apoptosis

Cancer Science

Volumn 99, Issue 11, 2008, Pages 2327-2335

  Zeng, Lihua ^a,b   Ou, Guangfei ^a   Itasaka, Satoshi ^a   Harada, Hiroshi ^a,c   Xie, Xuejun ^a,b   Shibuya, Keiko ^a   Kizaka Kondoh, Shinae ^a   Morinibu, Akiyo ^a   Shinomiya, Kazumi ^a   Hiraoka, Masahiro ^a,c  

^a KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^c KYOTO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; ANTINEOPLASTIC AGENT; HYPOXIA INDUCIBLE FACTOR 1; LUCIFERASE; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CANCER RADIOTHERAPY; CONTROLLED STUDY; DRUG TARGETING; ENDOTHELIUM CELL; ENZYME ACTIVATION; ENZYME INHIBITION; HUMAN; IN VIVO STUDY; INTERMETHOD COMPARISON; LUNG NON SMALL CELL CANCER; MICROVASCULATURE; NONHUMAN; PRIORITY JOURNAL; PROTEIN TARGETING; RADIATION DOSE; RADIATION DOSE FRACTIONATION; RADIOSENSITIVITY; REPORTER GENE; TUMOR CELL; TUMOR VOLUME; TUMOR XENOGRAFT;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; APOPTOSIS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; COMBINED MODALITY THERAPY; DRUG COMBINATIONS; ENDOTHELIAL CELLS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MICE; MICE, INBRED BALB C; OXONIC ACID; TEGAFUR; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 55449136468     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2008.00943.x     Document Type: Article

References (35)

1. Belka C, Nieder C, Molls M. Biological basis of combine radio- and chemotherapy. In: Brown JM, Metha MP, Mieder C, eds. Multimodal Concepts for Cytotoxic Drugs and Radiation Therapy. Germany: Springer, 2006; 3-17.
2. Thomlinson RH, Gray LH. The histological structure of some human lung cancers and the possible implications for radiotherapy. Br J Cancer 1955; 9: 539-49.
3. Gray LH, Conger AD, Ebert M, Hornsey S, Scott OC. The concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy. Br J Radiol 1953; 26: 638-48.
4. Vaupel P, Kallinowski F, Okunieff P. Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: A review. Cancer Res 1989; 49: 6449-65.
5. Brown JM, Wilson WR. Exploiting tumour hypoxia in cancer treatment. Nat Rev Cancer 2004; 4: 437-47.
6. Teicher BA. Hypoxia and drug resistance. Cancer Metastasis Rev 1994; 13: 139-68.
7. Harris AL. Hypoxia - a key regulatory factor in tumour growth. Nat Rev Cancer 2002; 2: 38-47.
8. Moeller BJ, Dewhirst MW. HIF-1 and tumour radiosensitivity. Br J Cancer 2006; 95: 1-5.
9. Wang GL, Jiang BH, Rue EA, Semenza GL. Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci USA 1995; 92: 5510-14.
10. Kallio PJ, Pongratz I, Gradin K, McGuire J, Poellinger L. Activation of hypoxia-inducible factor 1alpha: Posttranscriptional regulation and conformational change by recruitment of the Arnt transcription factor. Proc Natl Acad Sci USA 1997; 94: 5667-72.
11. Jaakkola P, Mole DR, Tian YM et al. Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science 2001; 292: 468-72.
12. Forsythe JA, Jiang BH, Iyer NV et al. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol 1996; 16: 4604-13.
13. Gorski DH, Beckett MA, Jaskowiak NT et al. Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation. Cancer Res 1999; 59: 3374-8.
14. Harada H, Kizaka-Kondoh S, Li G et al. Significance of HIF-1-active cells in angiogenesis and radioresistance. Oncogene 2007; 26: 7508-16.
15. Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 2003; 3: 721-32.
16. Shirasaka T, Shimamato Y, Ohshimo H et al. Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anticancer Drugs 1996; 7: 548-57.
17. Shirasaka T, Shimamoto Y, Fukushima M. Inhibition by oxonic acid of gastrointestinal toxicity of 5-fluorouracil without loss of its antitumor activity in rats. Cancer Res 1993; 53: 4004-9.
18. Sakata Y, Ohtsu A, Horikoshi N, Sugimachi K, Mitachi Y, Taguchi T. Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1.M tegafur-0.4.M gimestat-1.M otastat potassium) in advanced gastric cancer patients. Eur J Cancer 1998; 34: 1715-20.
19. Ohtsu A, Baba H, Sakata Y et al. Phase II study of S-1, a novel oral fluorophyrimidine derivative, in patients with metastatic colorectal carcinoma. S-1 Cooperative Colorectal Carcinoma Study Group. Br J Cancer 2000; 83: 141-5.
20. Shirasaka T, Nakano K, Takechi T et al. Antitumor activity of 1.M tegafur-0.4.M 5-chloro-2,4-dihydroxypyridine-1.M potassium oxonate (S-1) against human colon carcinoma orthotopically implanted into nude rats. Cancer Res 1996; 56: 2602-6.
21. Kawahara M, Furuse K, Segawa Y et al. Phase II study of S-1, a novel oral fluorouracil, in advanced non-small-cell lung cancer. Br J Cancer 2001; 85: 939-43.
22. Harada H, Shibuya K, Hiraoka M. Combination of antimetabolites and ionizing radiation. In: Brown JM, Metha MP, Mieder C, eds. Multimodal Concepts for Cytotoxic Drugs and Radiation Therapy. Germany: Springer, 2006; 19-34.
23. Harada K, Kawaguchi S, Supriatno Onoue T, Yoshida H, Sato M. Combined effects of the oral fluoropyrimidine anticancer agent, S-1 and radiation on human oral cancer cells. Oral Oncol 2004; 40: 713-19.
24. Harada H, Kizaka-Kondoh S, Hiraoka M. Optical imaging of tumor hypoxia and evaluation of efficacy of a hypoxia-targeting drug in living animals. Mol Imaging 2005; 4: 182-93.
25. Harada H, Kizaka-Kondoh S, Itasaka S et al. The combination of hypoxia-response enhancers and an oxygen-dependent proteolytic motif enables real-time imaging of absolute HIF-1 activity in tumor xenografts. Biochem Biophys Res Commun 2007; 360: 791-6.
26. Zeng L, Kizaka-Kondoh S, Itasaka S et al. Hypoxia inducible factor-1 influences sensitivity to paclitaxel of human lung cancer cell lines under normoxic conditions. Cancer Sci 2007; 98: 1394-401.
27. Harada H, Kizaka-Kondoh S, Hiraoka M. Mechanism of hypoxia-specific cytotoxicity of procaspase-3 fused with a VHL-mediated protein destruction motif of HIF-1alpha containing Pro564. FEBS Lett 2006; 580: 5718-22.
28. Moeller BJ, Cao Y, Li CY, Dewhirst MW. Radiation activates HIF-1 to regulate vascular radiosensitivity in tumors: Role of reoxygenation, free radicals, and stress granules. Cancer Cell 2004; 5: 429-41.
29. Yu LJ, Matias J, Scudiero DA et al. P450 enzyme expression patterns in the NCI human tumor cell line panel. Drug Metab Dispos 2001; 29: 304-12.
30. Wardman P. Chemical radiosensitizers for use in radiotherapy. Clin Oncol (R Coll Radiol) 2007; 19: 397-417.
31. Liu J, Harada H, Ogura M, Shibata T, Hiraoka M. Adenovirus-mediated hypoxia-targeting cytosine deaminase gene therapy enhances radiotherapy in tumour xenografts. Br J Cancer 2007; 96: 1871-8.
32. Znati CA, Rosenstein M, Boucher Y, Epperly MW, Bloomer WD, Jain RK. Effect of radiation on interstitial fluid pressure and oxygenation in a human tumor xenograft. Cancer Res 1996; 56: 964-8.
33. Moeller BJ, Dreher MR, Rabbani ZN et al. Pleiotropic effects of HIF-1 blockade on tumor radiosensitivity. Cancer Cell 2005; 8: 99-110.
34. Dang CV, Kim JW, Gao P, Yustein J. The interplay between MYC and HIF in cancer. Nat Rev Cancer 2008; 8: 51-6.
35. Kim JJ, Tannock IF. Repopulation of cancer cells during therapy: An important cause of treatment failure. Nat Rev Cancer 2005; 5: 516-25.